Grifols SA is a Spanish multinational healthcare company that specializes in the production and distribution of plasma-derived products. It was founded in 1909 in Barcelona, Spain, by Dr. Josep Antoni Grifols i Lucas. The company started as a small laboratory, but it has since grown into a global leader in the healthcare industry. Grifols produces a wide range of products including intravenous solutions, immunoglobulins, and albumin. It also offers diagnostic tools and services, including blood typing and screening, as well as research and development services for the pharmaceutical industry.
Grifols went public on the Spanish stock exchange in 2006, and its ADRs started trading on the NASDAQ in 2008. The company is listed under the ticker symbol GRFS. Grifols has a market capitalization of over $18 billion and is a component of several stock market indices, including the IBEX 35, Euro Stoxx 50, and S&P Global 1200.
Grifols has a strong presence in the United States, where it has 17 plasma collection centers and two manufacturing plants. The company also has operations in Europe, Asia, and Latin America. In addition to its core business of producing plasma-derived products, Grifols is also involved in developing new treatments for rare diseases and disorders. The company has several ongoing clinical trials for innovative therapies that aim to address unmet medical needs in areas such as neurology and immunology.